12:00 AM
Jan 17, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Actonel risedronate regulatory update

The American Association of Clinical Endocrinologists (AACE) released medical guidelines for the diagnosis and treatment of postmenopausal osteoporosis. The guidelines recommend 4 drugs as options for first-line treatment, including Prolia denosumab from Amgen; Fosamax alendronate from Merck; Actonel risedronate from Warner...

Read the full 181 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >